Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre platform. ClassAction.org first reported on the claims. The lawsuit alleges that tracking tools on Abbott’s FreeStyle Libre website expose private consumer information without their knowledge or consent. Its FreeStyle.Abbott website provides educational tools for the continuous glucose […]
abbott
Abbott launches Lingo over-the-counter CGM biosensor in the U.S.
Abbott (NYSE:ABT) announced today that it made its Lingo continuous glucose monitoring system available without a prescription in the U.S. The technology is now available in the U.S. at hellolingo.com, as well as in the United Kingdom. Lingo features a biosensor and mobile app designed for customers who want to improve their overall health and […]
Beta Bionics to pair bionic pancreas with Abbott FreeStyle Libre 3 Plus
Beta Bionics announced that it partnered with Abbott (NYSE:ABT) to integrate the company’s CGM with its automated insulin delivery system. The companies plan to combine Abbott’s FreeStyle Libre 3 Plus continuous glucose monitor (CGM) with the Beta Bionics iLet bionic pancreas. According to Beta Bionics, this will make iLet the first available AID system to […]
Abbott grants $1.6M to ADA in new diabetes collaboration
Abbott (NYSE:ABT) and the American Diabetes Association (ADA) announced a collaboration to support people with diabetes, obesity and metabolic dysfunction. Through the collaboration, ADA plans to review and consolidate evidence to help healthcare professionals understand the unique nutritional needs associated with diabetes, obesity and metabolic dysfunction. ADA also intends to assess the role nutrition formulas […]
The 9 largest diabetes technology companies in the world
Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
Abbott, Medtronic partner to connect CGM, insulin delivery systems
Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) today announced a global partnership pairing Abbott CGMs with Medtronic insulin delivery systems. The partnership aims to collaborate on a system based on Abbott’s FreeStyle Libre continuous glucose monitors (CGMs) with Medtronic’s automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as […]
Abbott recalls some FreeStyle Libre 3 sensors in U.S.
Abbott (NYSE:ABT) announced today that it initiated a voluntary recall for a small number of FreeStyle Libre 3 continuous glucose monitor (CGM) sensors. The company distributed the affected sensors during the first half of May 2024. Abbott did not disclose the number of sensors affected but said the recall affects a small subset of FreeStyle […]
Report: Court says SiBio can’t sell CGM in some European countries amid Abbott IP battle
JUVE-Patent reports that The Hague recently handed down two new decisions in a CGM patent battle between Abbott and SiBio. One case saw an Abbott patent infringement application shot down, while the other granted the U.S. medtech giant’s claim. The granted one could mean SiBio can’t distribute its CGMs in Germany, France, the Netherlands and […]
The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions
The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]
Why Abbott acquired Bigfoot Biomedical and its smart insulin pens
When Abbott (NYSE:ABT) acquired Bigfoot Biomedical in September 2023, it took the final step to build upon a multi-year relationship. The medtech giant had a long-term, vested interest in Bigfoot, a maker of a smart insulin management system. It dates back to 2017, with Abbott even leading a financing round for Bigfoot in 2020. “We […]
